

Subject: FDA approves oral disintegrating tablet QmiizODT™

The U.S. Food and Drug Administration (FDA) recently announced the approval of an oral disintegrating tablet form of meloxicam called QmiizODT.¹ Meloxicam is a popular choice among prescribed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), used for mild to moderate pain. QmiizODT is indicated for the same uses² as other forms of meloxicam (generic tablets and branded Vivlodex® capsules) and offers the added convenience of a tablet that dissolves rapidly on the tongue. For patients who experience difficulty swallowing, QmiizODT may offer an advantage; otherwise, generic meloxicam tablets are an equally effective, safe, and a more cost-effective choice.

The Impact

NSAIDs are a leading drug class (#5) based on cost at First Script and meloxicam is frequently prescribed. There is potential for QmiizODT to gain popularity among prescribers for pain patients who *don't* experience difficulty swallowing. The First Script Smart Prior Authorization process is configured to identify initial QmiizODT prescription fills, and to provide authorization guidance and therapeutic equivalents that may be less costly prior to dispensing.

For more information, please contact your Account Manager or Account Pharmacist.

For additional information about QmiizODT, visit: <https://www.qmiiz.com>

1 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211210Orig1s000TOC.cfm

2 the relief of the signs and symptoms of osteoarthritis (OA) in adults; rheumatoid arthritis (RA) in adults; and juvenile rheumatoid arthritis (JRA) - pauciarticular and polyarticular course, in pediatric patients who weigh greater than or equal to 60 kg.